Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Other Events

Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Other Events
Item 8.01. Other Events

Story continues below

On September10, 2017,Idera Pharmaceuticals Inc. issued a press release announcing the presentation of positive phase 1 clinical data for the Company’s IMO-2125 drug delivered intratumorally in combination with ipilimumab. A copy of the press release is furnished as Exhibit99.1 to this report.

Item 8.01. Financial Statements and Exhibits


99.1Press release, dated September10, 2017, issued by Idera Pharmaceuticals,Inc.


EX-99.1 2 a17-21543_1ex99d1.htm EX-99.1 Exhibit 99.1     Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy   -  Data from Ongoing Phase 1/2 Study Presented at the 2017 European Society for Medical Oncology (ESMO) Congress —   – 4 of 9 (44%) Achieved RECIST v1.1 Responses,…
To view the full exhibit click here

About Idera Pharmaceuticals,Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

An ad to help with our costs